Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines

ABSTRACT Background The efficacy and safety profile of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have not been definitively established in immunocompromised patient populations. Patients with a known cancer diagnosis were hitherto excluded from trials of the vaccines currently in clinical use.Methods This study presents data on the safety and immune efficacy of the BNT162b2 (Pfizer-BioNTech) vaccine in 54 healthy controls and 151 mostly elderly patients with solid and haematological malignancies, respectively, and compares results for patients who were boosted with BNT162b2 at 3 weeks versus those who were not. Immune efficacy was measured as antibody seroconversion, T cell responses, and neutralisation of SARS-CoV-2 Wuhan strain and of a variant of concern (VOC) (B.1.1.7). We also collected safety data for the BNT162b2 vaccine up to 5 weeks following first dose.Findings The vaccine was largely well tolerated. However, in contrast to its very high performance in healthy controls (>90% efficacious), immune efficacy of a single inoculum in solid cancer patients was strikingly low (below 40%) and very low in haematological cancer patients (below 15%). Of note, efficacy in solid cancer patients was greatly and rapidly increased by boosting at 21-days (95% within 2 weeks of boost). Too few haematological cancer patients were boosted for clear conclusions to be drawn.Conclusions Delayed boosting potentially leaves most solid and haematological cancer patients wholly or partially unprotected, with implications for their own health; their environment and the evolution of VOC strains. Prompt boosting of solid cancer patients quickly overcomes the poor efficacy of the primary inoculum in solid cancer patients.RESEARCH IN CONTEXT Evidence before this study Some cancer patients have been shown to exhibit sustained immune dysregulation, inefficient seroconversion and prolonged viral shedding as a consequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Consequently, their exclusion and, in particular, the exclusion of patients receiving systemic anti-cancer therapies, from the registry trials of the 5 approved COVID-19 vaccines raises questions about the efficacy and safety of SARS-CoV-2 vaccination in this patient population. In addition, whilst the change in the UK’s dosing interval to 12-weeks aimed to maximise population coverage, it is unclear whether this strategy is appropriate for cancer patients and those on systemic anti-cancer therapies.Added value of this study We report that the RNA-based SARS-CoV-2 BNT162b2 vaccine administered in cancer patients was well tolerated, and we provide first insights into both antibody and T cell responses to the vaccine in an immunocompromised patient population.Implications of all the available evidence In cancer patients, one dose of 30ug of BNT162b2 yields poor vaccine efficacy, as measured by seroconversion rates, viral neutralisation capacity and T cell responses, at 3- and 5-weeks following the first inoculum. Patients with solid cancers exhibited a significantly greater response following a booster at 21-days. These data support prioritisation of cancer patients for an early (21-day) second dose of the BNT162b2 vaccine. Given the globally poor responses to vaccination in patients with haematological cancers, post-vaccination serological testing, creation of herd immunity around these patients using a strategy of ‘ring vaccination’, and careful follow-up should be prioritised..

Medienart:	Preprint

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	bioRxiv.org - (2023) vom: 23. Okt. Zur Gesamtaufnahme - year:2023

Sprache:	Englisch

Beteiligte Personen:

Monin-Aldama, Leticia [VerfasserIn] Laing, Adam G. [VerfasserIn] Muñoz-Ruiz, Miguel [VerfasserIn] McKenzie, Duncan R [VerfasserIn] del Molino del Barrio, Irene [VerfasserIn] Alaguthurai, Thanussuyah [VerfasserIn] Domingo-Vila, Clara [VerfasserIn] Hayday, Thomas S. [VerfasserIn] Graham, Carl [VerfasserIn] Seow, Jeffrey [VerfasserIn] Abdul-Jawad, Sultan [VerfasserIn] Kamdar, Shraddha [VerfasserIn] Harvey-Jones, Elizabeth [VerfasserIn] Graham, Rosalind [VerfasserIn] Cooper, Jack [VerfasserIn] Khan, Muhammad [VerfasserIn] Vidler, Jennifer [VerfasserIn] Kakkassery, Helen [VerfasserIn] Shubhankar, Sinha [VerfasserIn] Davis, Richard [VerfasserIn] Dupont, Liane [VerfasserIn] Quijorna, Isaac Francos [VerfasserIn] Lee, Puay [VerfasserIn] Eum, Josephine [VerfasserIn] Poole, Maria Conde [VerfasserIn] Joseph, Magdalene [VerfasserIn] Davies, Daniel [VerfasserIn] Wu, Yin [VerfasserIn] Montes, Ana [VerfasserIn] Harries, Mark [VerfasserIn] Rigg, Anne [VerfasserIn] Spicer, James [VerfasserIn] Malim, Michael H [VerfasserIn] Fields, Paul [VerfasserIn] Patten, Piers [VerfasserIn] Rosa, Francesca Di [VerfasserIn] Papa, Sophie [VerfasserIn] Tree, Tim [VerfasserIn] Doores, Katie [VerfasserIn] Hayday, Adrian C. [VerfasserIn] Irshad, Sheeba [VerfasserIn]

Links:	Volltext [kostenfrei]

Themen:	570 Biology

doi:	10.1101/2021.03.17.21253131

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	XBI020169132